View in EDS

The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.

Saved in:
Bibliographic Details
Title: The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.
Authors: Hernández-Blanco C; Internal Medicine Department, University Hospital La Paz, Madrid, Spain.; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain., Al-Akioui-Sanz K; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; CNIO Pediatric OncoHematology Clinical Research Unit, Madrid, Spain., Herrera L; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain., Aguirre-Portolés C; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; CNIO Pediatric OncoHematology Clinical Research Unit, Madrid, Spain., Lozano-Ojalvo D; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Food Science Research Institute (CIAL, CSIC-UAM), Madrid, Spain., Pérez-Rodriguez L; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Cano-Ochando J; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Microbiology National Centre, Instituto de Salud Carlos III, Madrid, Spain., Guerra-García P; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Clinical Trials Unit (UCICEC), University Hospital La Paz, Madrid, Spain., Martín-Quirós A; Emergency Unit, Internal Medicine Department, University Hospital La Paz, Madrid, Spain., Vicario JL; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain., Santos S; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain., Pérez-Vaquero MÁ; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain., Vesga MÁ; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain., Borobia AM; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Clinical Trials Unit (UCICEC), University Hospital La Paz, Madrid, Spain., Carcas AJ; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Clinical Trials Unit (UCICEC), University Hospital La Paz, Madrid, Spain.; Faculty of Medicine Universidad Autónoma de Madrid, Madrid, Spain., Balas A; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain., Moreno MÁ; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain., Pérez de Diego R; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain., Gasior M; Hematology Department, Hospital Universitario La Paz, Madrid, Spain., Soria B; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Institute of Bioengineering, Miguel Hernández University, Elche, Alicante, Spain., Eguizabal C; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain., Pérez-Martínez A; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; CNIO Pediatric OncoHematology Clinical Research Unit, Madrid, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Pediatric Hemato-Oncology Department, University Hospital La Paz, Madrid, Spain.; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.; Faculty of Medicine Universidad Autónoma de Madrid, Madrid, Spain.
Source: IScience [iScience] 2024 Dec 27; Vol. 28 (2), pp. 111698. Date of Electronic Publication: 2024 Dec 27 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39877904
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hernández-Blanco+C%22">Hernández-Blanco C</searchLink>; Internal Medicine Department, University Hospital La Paz, Madrid, Spain.; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Al-Akioui-Sanz+K%22">Al-Akioui-Sanz K</searchLink>; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; CNIO Pediatric OncoHematology Clinical Research Unit, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Herrera+L%22">Herrera L</searchLink>; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Aguirre-Portolés+C%22">Aguirre-Portolés C</searchLink>; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; CNIO Pediatric OncoHematology Clinical Research Unit, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Lozano-Ojalvo+D%22">Lozano-Ojalvo D</searchLink>; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Food Science Research Institute (CIAL, CSIC-UAM), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez-Rodriguez+L%22">Pérez-Rodriguez L</searchLink>; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Cano-Ochando+J%22">Cano-Ochando J</searchLink>; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Microbiology National Centre, Instituto de Salud Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Guerra-García+P%22">Guerra-García P</searchLink>; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Clinical Trials Unit (UCICEC), University Hospital La Paz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Martín-Quirós+A%22">Martín-Quirós A</searchLink>; Emergency Unit, Internal Medicine Department, University Hospital La Paz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Vicario+JL%22">Vicario JL</searchLink>; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Santos+S%22">Santos S</searchLink>; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez-Vaquero+MÁ%22">Pérez-Vaquero MÁ</searchLink>; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Vesga+MÁ%22">Vesga MÁ</searchLink>; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Borobia+AM%22">Borobia AM</searchLink>; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Clinical Trials Unit (UCICEC), University Hospital La Paz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Carcas+AJ%22">Carcas AJ</searchLink>; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; Clinical Trials Unit (UCICEC), University Hospital La Paz, Madrid, Spain.; Faculty of Medicine Universidad Autónoma de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Balas+A%22">Balas A</searchLink>; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Moreno+MÁ%22">Moreno MÁ</searchLink>; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez+de+Diego+R%22">Pérez de Diego R</searchLink>; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Gasior+M%22">Gasior M</searchLink>; Hematology Department, Hospital Universitario La Paz, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Soria+B%22">Soria B</searchLink>; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Institute of Bioengineering, Miguel Hernández University, Elche, Alicante, Spain.<br /><searchLink fieldCode="AU" term="%22Eguizabal+C%22">Eguizabal C</searchLink>; Cell Therapy, Stem Cells and Tissues Group, Biobizkaia Health Research Institute, Barakaldo, Spain.; Advanced Therapies Unit, Basque Center of Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Red de Inmunoterapia del Cáncer 'REINCA' (RED2022-134831-T), Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez-Martínez+A%22">Pérez-Martínez A</searchLink>; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; CNIO Pediatric OncoHematology Clinical Research Unit, Madrid, Spain.; Red Española de Terapias Avanzadas (TERAV), Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS RD21/0017/0024, RICORS RD24/0014/0025, RICORS RD21/0017/0025, RICORS RD24/0014/0024), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.; Pediatric Hemato-Oncology Department, University Hospital La Paz, Madrid, Spain.; Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.; Faculty of Medicine Universidad Autónoma de Madrid, Madrid, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101724038%22">IScience</searchLink> [iScience] 2024 Dec 27; Vol. 28 (2), pp. 111698. <i>Date of Electronic Publication: </i>2024 Dec 27 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101724038 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2589-0042 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225890042%22">25890042 </searchLink><i>NLM ISO Abbreviation: </i>iScience <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39877904
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.isci.2024.111698
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 111698
    Titles:
      – TitleFull: The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hernández-Blanco C
      – PersonEntity:
          Name:
            NameFull: Al-Akioui-Sanz K
      – PersonEntity:
          Name:
            NameFull: Herrera L
      – PersonEntity:
          Name:
            NameFull: Aguirre-Portolés C
      – PersonEntity:
          Name:
            NameFull: Lozano-Ojalvo D
      – PersonEntity:
          Name:
            NameFull: Pérez-Rodriguez L
      – PersonEntity:
          Name:
            NameFull: Cano-Ochando J
      – PersonEntity:
          Name:
            NameFull: Guerra-García P
      – PersonEntity:
          Name:
            NameFull: Martín-Quirós A
      – PersonEntity:
          Name:
            NameFull: Vicario JL
      – PersonEntity:
          Name:
            NameFull: Santos S
      – PersonEntity:
          Name:
            NameFull: Pérez-Vaquero MÁ
      – PersonEntity:
          Name:
            NameFull: Vesga MÁ
      – PersonEntity:
          Name:
            NameFull: Borobia AM
      – PersonEntity:
          Name:
            NameFull: Carcas AJ
      – PersonEntity:
          Name:
            NameFull: Balas A
      – PersonEntity:
          Name:
            NameFull: Moreno MÁ
      – PersonEntity:
          Name:
            NameFull: Pérez de Diego R
      – PersonEntity:
          Name:
            NameFull: Gasior M
      – PersonEntity:
          Name:
            NameFull: Soria B
      – PersonEntity:
          Name:
            NameFull: Eguizabal C
      – PersonEntity:
          Name:
            NameFull: Pérez-Martínez A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 12
              Text: 2024 Dec 27
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2589-0042
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: IScience
              Type: main
ResultId 1